The Centers for Medicare and Medicaid has become aware that the significant price increases implemented over the years by Mylan Pharmaceuticals Inc. for its EpiPen emergency allergy treatment is far from “a one-off” situation, according to Acting Administrator Andy Slavitt.
“The data tells me there’s not something highly unique about that pattern of pricing increase,” he told the BioPharma Congress...